Renazide en es it fr

Renazide Brand names, Renazide Analogs

Renazide Brand Names Mixture

  • Zylet (0.5% loteprednol etabonate + 0.3% tobramycin)

Renazide Chemical_Formula


Renazide RX_link

No information avaliable

Renazide fda sheet

Renazide msds (material safety sheet)

Renazide MSDS

Renazide Synthesis Reference

No information avaliable

Renazide Molecular Weight

389.879 g/mol

Renazide Melting Point


Renazide H2O Solubility

No information avaliable

Renazide State


Renazide LogP


Renazide Dosage Forms

Tablets (oral, 5mg)

Renazide Indication

Cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Renazide Pharmacology

Like other thiazides, cyclothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Cyclothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Cyclothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.

Renazide Absorption

No information avaliable

Renazide side effects and Toxicity

Oral LD50 in mouse is > 10000 mg/kg, and > 4000 mg/kg in rat. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.

Renazide Patient Information

Renazide Organisms Affected

Humans and other mammals